title: Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
abstract: Previously we have reported that, cycloart-23-ene-3β, 25-diol (called as B2) and L-glutamine stimulated glucagon like peptide-1 (GLP-1) (7-36) amide secretion diabetic rats. The objective of present investigation was to investigate the concomitant administration of cycloart-23-ene-3β, 25-diol+sitagliptin and L-glutamine+sitagliptin in streptozotocin - nicotinamide induced diabetic Sprague Dawley. Type 2 diabetes was induced in overnight fasted male Sprague Dawley rats pre-treated with nicotinamide (100 mg/kg, i.p.) followed by administration of streptozotocin (55 mg/kg, i.p.) 20 min after. The rats were divided into; I- non-diabetic, II- diabetic control, III- Sitagliptin (5 mg/kg, p.o.)+cycloart-23-ene-3β, 25-diol (1 mg/kg, p.o.), IV- Sitagliptin (5 mg/kg, p.o.)+L-glutamine (1000 mg/kg, p.o.). The concomitant treatment of cycloart-23-ene-3β, 25-diol and L-glutamine with sitagliptin was 8 weeks. Plasma glucose, body weight, food and water intake were determined every week. Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress were measured after 8(th) week treatment. Concomitant administration of cycloart-23-ene-3β, 25-diol and L-glutamine with sitagliptin significantly (p<0.001) reduced plasma glucose, glyoxylated haemoglobin, lipid profile and oxidative stress parameters compared to diabetic control groups. Both concomitant treatment increased plasma and pancreatic insulin as well as plasma and colonic active (GLP-1) (7-36) amide secretion. Histological analysis by Gomori staining observed less destruction of pancreatic β cells. The result obtained from this study; it is concluded that concomitant administration of cycloart-23-ene-3β, 25-diol+sitagliptin and L-glutamine+sitagliptin showed additive antihyperglycaemic effect in diabetic rats.
authors.affiliation: Department of Pharmacology, PES's Modern College of Pharmacy, Pune, India.
authors.forename: Sachin L
authors.initials: SL
authors.lastname: Badole
authors.forename: Swapnil M
authors.initials: SM
authors.lastname: Chaudhari
authors.forename: Pranita P
authors.initials: PP
authors.lastname: Bagul
authors.forename: Sagar P
authors.initials: SP
authors.lastname: Mahamuni
authors.forename: Rekha D
authors.initials: RD
authors.lastname: Khose
authors.forename: Anuja C
authors.initials: AC
authors.lastname: Joshi
authors.forename: Chandrashekhar G
authors.initials: CG
authors.lastname: Raut
authors.forename: Anand A
authors.initials: AA
authors.lastname: Zanwar
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003106:Colon / Q000187:drug effects / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004327:Drinking Behavior / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000097:blood / Q000378:metabolism*; D005973:Glutamine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D009536:Niacinamide; D018384:Oxidative Stress / Q000187:drug effects*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068900:Sitagliptin Phosphate; D013194:Staining and Labeling; D013311:Streptozocin; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014315:Triterpenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D005973:Glutamine; D006442:Glycated Hemoglobin; D007328:Insulin; D009536:Niacinamide; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D013311:Streptozocin; D014230:Triazoles; D014315:Triterpenes; C102764:9,19-cycloart-23-ene-3,25-diol
references.citation: Exp Biol Med (Maywood). 2012 May;237(5):481-90
references.pmid: 22619373
references.citation: Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G943-9
references.pmid: 15677555
references.citation: Diabetes Obes Metab. 2007 Mar;9(2):194-205
references.pmid: 17300595
references.citation: Fitoterapia. 2003 Feb;74(1-2):7-13
references.pmid: 12628387
references.citation: Methods Enzymol. 1981;77:398-405
references.pmid: 7329316
references.citation: Lancet. 2006 Nov 11;368(9548):1696-705
references.pmid: 17098089
references.citation: Clin Chim Acta. 2005 Sep;359(1-2):101-8
references.pmid: 15893742
references.citation: Indian J Clin Biochem. 2011 Jan;26(1):74-7
references.pmid: 22211019
references.citation: J Clin Anesth. 2004 Feb;16(1):4-6
references.pmid: 14984852
references.citation: Chem Biol Interact. 2013 Apr 25;203(2):530-41
references.pmid: 23466488
references.citation: Eur J Pharmacol. 2010 Apr 25;632(1-3):103-9
references.pmid: 20122920
references.citation: Exp Toxicol Pathol. 2012 Sep;64(6):651-8
references.pmid: 21208790
references.citation: Am J Clin Pathol. 1950 Jul;20(7):665-6
references.pmid: 15432365
references.citation: J Biol Chem. 1972 May 25;247(10):3170-5
references.pmid: 4623845
references.citation: Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27
references.pmid: 14984018
references.citation: Clin Nutr. 2011 Feb;30(1):124-9
references.pmid: 20705374
references.citation: Fundam Clin Pharmacol. 2005 Feb;19(1):1-16
references.pmid: 15660956
references.citation: J Lipid Res. 1989 Dec;30(12):1827-34
references.pmid: 2621411
references.citation: Biochem J. 1971 Aug;123(5):805-14
references.pmid: 4399399
references.citation: Mol Cell Endocrinol. 1988 Sep;59(1-2):83-91
references.pmid: 2974003
references.citation: Science. 1973 Feb 9;179(4073):588-90
references.pmid: 4686466
references.citation: Eur J Pharmacol. 2013 Jan 5;698(1-3):470-9
references.pmid: 23117087
references.citation: Drugs Today (Barc). 2007 Jan;43(1):13-25
references.pmid: 17315049
references.citation: J Vet Sci. 2005 Sep;6(3):197-200
references.pmid: 16131821
references.citation: Diab Vasc Dis Res. 2006 Dec;3(3):159-65
references.pmid: 17160910
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Biochim Biophys Acta. 1979 Jan 4;582(1):67-78
references.pmid: 760819
references.citation: Diabetes. 1998 Feb;47(2):224-9
references.pmid: 9519717